Characteristics and outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting.

Bibliographic Details
Title:	Characteristics and outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting.
Authors:	Kersting, David¹ (AUTHOR), Kim, Moon-Sung² (AUTHOR), Puellen, Lukas³ (AUTHOR), Seidl-Rathkopf, Kathi⁴ (AUTHOR), Schinwald, Nicole⁴ (AUTHOR), Mpofu, Philani⁵ (AUTHOR), Altomare, Ivy⁵ (AUTHOR), Sujenthiran, Arun⁶ (AUTHOR), Royce, Trevor Joseph⁵ (AUTHOR), Buhl, Christoph⁴ (AUTHOR), Grünwald, Viktor⁷ (AUTHOR), Herrmann, Ken¹ (AUTHOR), Kleesiek, Jens² (AUTHOR), Hadaschik, Boris A.³ (AUTHOR)
Source:	Journal of Clinical Oncology. 2024 Supplement 4, Vol. 42, p143-143. 235p.
Database:	Supplemental Index

Description
ISSN:	0732183X
DOI:	10.1200/JCO.2024.42.4_suppl.143